157 related articles for article (PubMed ID: 34927575)
21. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
22. Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells.
Yamaguchi N; Osaki M; Onuma K; Yumioka T; Iwamoto H; Sejima T; Kugoh H; Takenaka A; Okada F
Anticancer Res; 2017 Jun; 37(6):2985-2992. PubMed ID: 28551636
[TBL] [Abstract][Full Text] [Related]
23. AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis.
Wang Q; Gao S; Shou Y; Jia Y; Wei Z; Liu Y; Shi J; Miao D; Miao Q; Zhao C; Liu C; Yang H; Xu T; Zhang X
Int J Biol Sci; 2023; 19(4):1266-1283. PubMed ID: 36923928
[TBL] [Abstract][Full Text] [Related]
24. Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
J Cell Mol Med; 2024 May; 28(9):e18329. PubMed ID: 38693863
[TBL] [Abstract][Full Text] [Related]
25. N
Chen Y; Lu Z; Qi C; Yu C; Li Y; Huan W; Wang R; Luo W; Shen D; Ding L; Ren L; Xie H; Xue D; Wang M; Ni K; Xia L; Qian J; Li G
Mol Cancer; 2022 May; 21(1):111. PubMed ID: 35538475
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
Lichner Z; Saleeb R; Butz H; Ding Q; Nofech-Mozes R; Riad S; Farag M; Varkouhi AK; Dos Santos CC; Kapus A; Yousef GM
FASEB J; 2019 Jan; 33(1):1347-1359. PubMed ID: 30148679
[TBL] [Abstract][Full Text] [Related]
27. CircRNA SCARB1 Promotes Renal Cell Carcinoma Progression Via Mir- 510-5p/SDC3 Axis.
Sun J; Pan S; Cui H; Li H
Curr Cancer Drug Targets; 2020; 20(6):461-470. PubMed ID: 32271695
[TBL] [Abstract][Full Text] [Related]
28. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
[TBL] [Abstract][Full Text] [Related]
29. Nc886 promotes renal cancer cell drug-resistance by enhancing EMT through Rock2 phosphorylation-mediated β-catenin nuclear translocation.
Gao W; Zhang S; Guorong L; Liu Q; Zhu A; Gui F; Zou Y; Wu Y; Luo Y; Hong Z
Cell Cycle; 2022 Feb; 21(4):340-351. PubMed ID: 34974812
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells.
Zhu Y; Xu L; Zhang J; Hu X; Liu Y; Yin H; Lv T; Zhang H; Liu L; An H; Liu H; Xu J; Lin Z
Cancer Sci; 2013 Aug; 104(8):1052-61. PubMed ID: 23578198
[TBL] [Abstract][Full Text] [Related]
31. G-Protein-coupled Estrogen Receptor 1 Agonist G-1 Perturbs Sunitinib Resistance-related Phosphoproteomic Signatures in Renal Cell Carcinoma.
Chen SK; Wang YC; Lin TY; Wu HJ; Huang CJ; Ku WC
Cancer Genomics Proteomics; 2021; 18(3):207-220. PubMed ID: 33893075
[TBL] [Abstract][Full Text] [Related]
32. Long Non-Coding RNA LOC648987 Promotes Proliferation and Metastasis of Renal Cell Carcinoma by Regulating Epithelial-Mesenchymal Transition.
Su Y; Zhou L; Yu Q; Lu J; Liu W
Technol Cancer Res Treat; 2021; 20():1533033821997834. PubMed ID: 33858283
[TBL] [Abstract][Full Text] [Related]
33. QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis.
Zhao T; Zhou Y; Wang Q; Yi X; Ge S; He H; Xue S; Du B; Ge J; Dong J; Qu L; Wang L; Zhou W
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34036385
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
35. Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells.
Meng L; Chen D; Meng G; Lu L; Han C
FEBS Open Bio; 2021 Mar; 11(3):921-931. PubMed ID: 33455080
[TBL] [Abstract][Full Text] [Related]
36. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
Zhang L; Xie D; Lei Y; Na A; Zhu L
Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
[No Abstract] [Full Text] [Related]
37. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics.
Wang Y; Liu X; Gong L; Ding W; Hao W; Peng Y; Zhang J; Cai W; Gao Y
Br J Pharmacol; 2023 Dec; 180(23):2937-2955. PubMed ID: 37740648
[TBL] [Abstract][Full Text] [Related]
39. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA.
Qu L; Ding J; Chen C; Wu ZJ; Liu B; Gao Y; Chen W; Liu F; Sun W; Li XF; Wang X; Wang Y; Xu ZY; Gao L; Yang Q; Xu B; Li YM; Fang ZY; Xu ZP; Bao Y; Wu DS; Miao X; Sun HY; Sun YH; Wang HY; Wang LH
Cancer Cell; 2016 May; 29(5):653-668. PubMed ID: 27117758
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Jin J; Xie Y; Zhang JS; Wang JQ; Dai SJ; He WF; Li SY; Ashby CR; Chen ZS; He Q
Drug Resist Updat; 2023 Mar; 67():100929. PubMed ID: 36739809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]